AntiOp Partners With Reckitt Benckiser Pharmaceuticals Inc. To Develop Nasally Administered Treatment For Opioid Overdose

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Ky.--(BUSINESS WIRE)--AntiOp, Inc., a Kentucky company founded by Dr. Daniel Wermeling, has signed an agreement with Reckitt Benckiser Pharmaceuticals, Inc. to accelerate production and worldwide marketing of intranasal naloxone, a drug designed to treat opioid overdose.

Help employers find you! Check out all the jobs and post your resume.

Back to news